

Antibiotic stewardship in Norway: are strategies for rational use of antibiotics followed in Norwegian healthcare system?

Girma Gutema¹, Helle Håkonsen¹, Ephrem Engidawork², Else-Lydia Toverud¹

¹School of Pharmacy, University of Oslo, ²School of Pharmacy, Addis Ababa University

Abstract

Objective: Resistance has been a major challenge since the development of antibiotics and countries have been working to curb it. As part of this effort, Norway has been striving to maintain low consumption of antibiotics and drug resistance. This paper aims to review the findings of studies in this regard as an attempt to investigate if the impacts of the country's antibiotic stewardship strategies are in line with the intention.

Method: A literature review was performed by searching MEDLINE/PubMed to identify peer reviewed articles which dealt with antibiotic use and resistance in Norway. Studies conducted after the year 2000, when a comprehensive national action plan against antibiotic resistance was initiated, were included and the search terms were antibiotic, antimicrobials, resistance and Norway.

Results: A total of 229 articles were identified of which 75 were included in the review. In primary healthcare settings, hospitals and nursing homes, research themes like adherence to specific institutional guidelines, consumption of antibiotics, patterns of antibiotic resistance, infection prevention/control, as well as resistance profiling were taken up by investigators. Most of the findings highlighted that healthcare facilities are striving to adhere to guidelines and

implement strategies outlined in the national strategic plan, despite some challenges. This has resulted in restricting the use of antibiotics thereby maintaining favorable environment to promote their prudent use.

Conclusion: By and large, the findings affirm that the Norwegian healthcare system is characterized by a conservative use of antibiotics that has a positive impact on resistance containment. The authorities need to work further on issues such as adherence to guidelines and infection prevention/control so as to further maximize the prevailing good conditions.

Key words: Antibiotics, drug use, resistance, stewardship, Norway **Introduction**

Over the last seven decades, antibiotic chemotherapy constituted man's effective strategy to fight infections with remarkable gains [1]. These therapeutic agents also revolutionized medical practices in such specific interventions as surgery, oncology and in the transplantation of internal organs [2]. However, as part of their evolutionary mechanisms to cope, pathogenic microorganisms have been known to develop resistance towards antibiotics ever since the discovery of penicillin [3]. Nonetheless, owing to the understandable excitement as a result of strong antibiotic effects, the potential of penicillin as a therapeutic agent overshadowed the resistance issue. Thus, it was evident even from the earlier phases of the human-pathogen battle that pathogenic microbes carry capabilities to counter-act antibiotics, though the important concept that continuous suboptimal exposures to antibiotics augment such abilities of the microbes was demonstrated later on [4]. At the level of the community and healthcare institutions, numerous studies have documented the causal associations between antibiotic utilizations and resistance [5-10].

Currently, resistance to antibiotics is considered to be one of the most important public health problems at global level [11, 12]. Over the last two decades, health authorities including the WHO have recommended member states to draft relevant policies and commit resources to tackle the problem. In Norway, there had traditionally been stringent use of antibiotics but resistance problems associated with Methicillin-Resistant *Staphylococcus Aureus* (MRSA) and *Mycobacterium Tuberculosis* have recently turned challenging because of immigration and international travels. Accordingly, Norway has been working by designing relevant antibiotic stewardship strategies and implementing them institutionally. Antibiotic stewardship encompasses all regulatory, operational, educational and institutional mechanisms and activities undertaken to ensure the prudent use of antibiotics [4]. The set of ideas in the concept of antibiotic stewardship propose valuable solutions to the combined problems of increasing antibiotic resistance, the declining number of new antibiotics introduced to the market, and their suboptimal use in human health and beyond [2].

The Framework of Antibiotic Stewardship Strategy in Norway

In response to the escalating challenges, the Norwegian Ministry of Health and Social Affairs issued a comprehensive national action plan against antibiotic resistance in 2000 [13]. The action plan outlined a holistic approach for monitoring antibiotic resistance both in the human and veterinary sectors. Directly driven by the action plan, the NORM and NORM-VET programs were established to provide microbiologically and epidemiologically valid data sets on the occurrence and distribution of antibiotic resistance in Norway. The working groups of the monitoring programs have been publishing annual reports since the establishment and the

programs are regarded as valuable tools for setting policies, assessing risks and evaluating interventions in the country [14].

Following the expiry of the earlier action plan period, a comprehensive report was issued by the Norwegian Institute of Public Health in 2004. This report, which is said to have formed the basis for the Norwegian antibiotic stewardship strategies in the years to follow, stressed on the need for sustained surveillance of both antibiotic utilization and resistance in the country. After this, in 2008, an integrated national strategy for prevention of infections in the health service and antibiotic resistance (2008-2012) was issued. The strategy encompassed infection prevention in controlling antibiotic use and resistance [15]. Elsewhere, studies recommended that antibiotic stewardship programs should be either fully integrated or work closely with infection prevention/control programs [16, 17]. The strategy outlined relevant measures in many sectors, and at various levels. Examples of specific activities to achieve the national goal to contain antibiotic resistance include, among others, restricted use of antibiotics especially the wide spectrum ones and development of guidelines for antibiotic prescribing. Fig.1 below depicts the four angles along which the national surveillance of antibiotic resistance in Norway has been organized [15]. It's quite clear that the different axes illustrate the resistance epidemiology from different perspectives which are, indeed, complementary to each other.




Figure 1: Organization of the national surveillance of antimicrobial resistance in Norway

Aiming to capitalize on what had been done since the implementation of the first action plan in 2000, the three broad national goals to be achieved during the 2008-2012 are indicated in Table1 below:

Table1: The three broad national goals on antibiotic stewardship in Norway [2008-2012]

National Goal	Planned Achievement [2008-2012]
One	The occurrence of antibiotic resistance in Norway shall not increase
Two	The occurrence of infections acquired in the health service in Norway shall be reduced
Three	Knowledge about occurrence, causal relations and effects of measures to prevent infections in the health service and antibiotic resistance shall be improved

Both in qualitative and quantitative terms, the three goals were subjective; yet they were each illustrated by a number of sub-targets channeling the various activities into these broader national goals [15].

Given this organizational and strategic frameworks of Norway's antibiotic stewardship program, it would be imperative to look into the actual practices underlying the country's healthcare system. As part of that, this paper aims to review the studies conducted in Norway, community or institution-based, after the year 2000 when such stewardship programs were put in place in an organized manner. The review of the findings may grossly show the impact of the stewardship program.

Methodology

This review was performed by searching MEDLINE (PubMed) to identify peer reviewed original research articles, which dealt with antibiotic use and resistance in Norway. Studies conducted after the year 2000, when a national comprehensive action plan against antibiotic resistance was

initiated, were included. The search terms used were: antibiotics, antimicrobials, resistance. Combining each search term with Norway led to the identification of 229 articles of which 75 were relevant for the review as indicated in Fig 2: The article excluded as irrelevant were those from other sectors like veterinary, aquaculture and animal husbandry, among others.




Figure 2: Flowchart for the literature search strategy

The reviews of the results in the articles are categorically presented under the settings where the studies were conducted, i.e., primary healthcare, hospitals and nursing homes. All along, articles that dealt with adherence to guidelines, prescribing patterns/consumption and infection prevention/control were presented as distinctive themes. Resistance issues are presented separately at the later part of results section.

Results

Primary Healthcare settings

Pertaining to adherence to treatment guidelines, Flottorp and coworkers reported that in some Norwegian primary healthcare settings, guidelines for the use of antibiotics are not strictly followed [18]. In a study to examine antibiotic prescribing patterns for acute respiratory tract infections as compared to national guidelines, Gjelstad *et al* [19] reported 41.2% adherence. On the other hand, Agdestein and his colleagues [20] reported adherence in 68% of cases for urinary tract infections by general practitioners. Moreover, it was also indicated that Norwegian dental service provisions are in accordance to the guidelines [21]. In other studies, however, not only adherence with treatment guidelines but also other simple practices such as the possibility of delaying prescription for infections like otitis [22] and enhanced consultation times with parents in pediatric diagnosis [23] are recommended as strategies to reduce antibiotic consumption and the risk of resistance. Out of curiosity on the controversy surrounding adherence to treatment regimens by patients as prescribers follow guidelines, Eide *et al* [24] reported 83% adherence and concluded that Norwegian guidelines for antibiotic treatment in primary healthcare appeared to be feasible with regard to patient adherence.

Another study showed low antibiotic prescription rates for childhood respiratory tract infections in Norwegian primary healthcare settings during 2004-5 [25]. However, this study indicated an overuse of macrolide antibiotics and extended spectrum penicillins. A prospective cohort study that followed prescription patterns of 145 general practitioners also corroborated the overuse of macrolides [26]. However, other studies reported improved use of wide spectrum

antibiotics in respiratory infection as a result of educational interventions and promoting delayed prescription among Norwegian general practitioners [27-29].

Furthermore, a study which assessed the utilization of 11 antibiotics prescribed by dentists reported the reliance of Norwegian dentists on phenoxymethylpenicillin as their 1st choice; suggesting low prevalence of antibiotic resistance among oral bacteria in Norway. It has been shown that the dentists' prescriptions accounted for 8% of the total national consumption of antibiotics [30]. The study generally showed trends that coincide with the conservative use of antibiotics that characterizes the Norwegian healthcare system [31-36].

Several lines of evidence have demonstrated the positive impact of Norway's antibiotics stewardship program on antibiotic consumption by children. For instance, according to a study [37] conducted on 22 randomly chosen children day-care centers in Oslo, the proportion of children treated for infections was reduced from 65% in 2000 to 50% in 2006. The same study reported that prescription following medical consultations decreased from 80% in 2000 to 50% in 2006. In relation to this, Lagerløv and his co-workers reported the age and gender disparity of pre-school children in antibiotics consumption [38]. Other studies also reported that antibiotic consumption in Norway show variations in magnitude among age and gender, with slight excess in consumption by female over male population and also among children and the elderly compared to other age groups [39-41].

The control, prevention and treatment of Tuberculosis (TB) have recently turned a challenge in Norway because of immigration and travels. From 1998-2009, the overall incidence rate of TB in Oslo was reported to be 2.6 per 100,000 person per year. The figure as adjusted to children from non-western origin was, however, 8.1 per 100,000 person per year, making TB a big challenge among this group in Norway [42]. In line with this, Farah *et al* [43] reported an overall

treatment success rate for TB in Norway to be 83% with marginal difference among patients born in the country and abroad, i.e., 79% and 86% respectively. In their study to determine the social and economic burdens of Directly Observed Treatment Short-course (DOTS) on patients, Sagbakken *et al* [44] recently reported that the practice of DOTS reflects societal power structures that influence the clinical interactions between health professionals and patients in Norway. Owing to the lack of individual patient negotiated schemes for the initiation of DOTS, the authors indicated high social costs related to the treatment for patients who attended school or had occupational obligations. In relation to this, a study reported the incidence rate for confirmed Methicillin-Resistant *Staphylococcus Aureus* (MRSA) infection in children less than 3 years of age to be 1.1 and 0.034 per 1000 persons per year for those adopted from abroad and other children, respectively, during 1995–2005. The study highlighted on the challenge posed by MRSA by indicating that such adopted children had 33% increased risk of being notified with MRSA infection, though the overall prevalence is still low in Norway as compared to other countries [45].

Hospitals

Kacelnik *et al* [46] indicated that the presence and contents of treatment guidelines vary greatly among the 37 Norwegian hospitals they assessed for adherence to guidelines in antibiotic prophylaxis for cholecystectomies. According to the authors, although many used guidelines to give focus mainly to at-risk patients who need antibiotics, there were cases in which antibiotics were advocated to patients where the benefits were doubtful. Eriksen *et al* [47] reported good adherence by maternity departments in Norwegian hospitals with national guidelines for antibiotics prophylaxis in connection with caesarean section (CS).

Pertinent to infection prevention/control in Norwegian hospitals, a study by Eriksen *et al* [48] reported only 8.3% of the 3,491 women who completed follow-up after CS experienced infections and 86% of such infections occurred after discharge. Analysis of risk factors for the occurrence of infection after CS showed that age above 29 years and the extent of wound contamination were independent risk factors. In line with this, it was reported elsewhere in Norway [49] that prophylactic use of methenamine hippurate significantly reduced the incidence of postoperative bacteriuria and urinary tract infection. In another study on the prevalence of post-operative infection, it was reported that antibiotic prophylaxis utilization was 58% during the seven years follow-up of a compiled data for orthopedic implants at a local hospital. According to the results of this study, which involved 2,421 patients, 6.5% of the patients developed post-operative infections, of which only 2.3% were deep [50].

Nosocomial infections are among the most serious problems in Norwegian hospitals because the carriers of such infections harbor and transmit them easily after discharge [51]. Perhaps, CTX-M-15 extended-spectrum beta-lactamase-producing (ESBL) *Klebsiella pneumoniae* is a common cause of hospital acquired infections and its outbreak in neonatal intensive care units is reported in 2008 [52]. Lohr *et al* [53] studied the fecal colonization of infants during such outbreaks and found out that they were putative fecal carriers of CTX-M-15 *K. pneumoniae* when discharged from hospital. Elsewhere, prematurity and treatment with antibiotics were reported as independent risk factors for colonization of infants during outbreak with ESBL-producing *K. pneumoniae* [54]. Outbreaks of infections caused by other strains like *Mycoplasma pneumoniae* [55], MRSA [56] and *Neisseria gonorrhoeae* [57] have also been reported in Norway sometimes over the last decade. Introduction and institutionalization of specific infection prevention/control protocol is said to be effective in reducing hospital acquired

infections in the country. For instance, through the implementation of a perioperative protocol, Hommelstad *et al* [58] reported a significant reduction in shunt infection.

Nursing homes

Investigators also shed light on Norwegian nursing homes vis-à-vis antibiotic stewardship over the last decade. With regards to the use of guidelines for antibiotics in such institutions, a recent study reported prescription adherence for 77% of urinary tract infections, 79% for respiratory tract infections, and 76% for skin and soft tissue infections. It was indicated that 63% of non-adherence had been attributed to Ciprofloxacin prescribing [59]. Other study also reported ciprofloxacin overuse in nursing homes [60]. Similarly, a point-prevalence study carried out in 44 Norwegian nursing homes indicated that prescriptions of antibiotics constituted 15% of the total number of prescriptions, of which two-third were used for prophylactic purposes [61]. On the other hand, a cross-sectional descriptive study that reported large variation in antibiotic use among Norwegian nursing homes estimated that in 2003, antibiotic consumptions in such institutions accounted for 6% of human antibacterial use in Norway. According to this study, methenamine, a urinary prophylactic agent, represented 50% of the consumption [62]. With this regards, comparable results have also recently been reported in another study [63].

Owing to the conditions of such institutions which depend on the severity of specific patients residing in them, infection prevention/control in nursing homes are, however, said to have challenges that call for utmost attention in Norway [64]. In their recent study, Bergman *et al* [65] concluded that uses of preventive agents for urinary tract infections in some Norwegian nursing homes are not evidence-based. Moreover, there are reports indicating that nosocomial infections pose serious threats to the elderly in some long-term-care facilities in the country [66, 67].

Hence, at present, there is an increasing emphasis on infection prevention and control in such facilities [68].

Resistance Studies

Ecological surveillances of the resistance levels and trends have been another important theme taken up by investigators in Norwegian health systems. In the study undertaken to investigate aminoglycoside resistance in *Escherichia coli* and *K. pneumoniae* in 49 cultured isolates during 2000–2009 in Western Norway, Lindemann and his co-workers [69] reported resistance to more than 3 aminoglycosides in 92% of the isolates. For *enterococci* isolates from various ward patients in Norway and other Scandinavian countries, 11-25% resistance rates towards gentamicin are reported elsewhere [70]. Besides, the prevalence of beta-lactamase-producing bacteria in sub-gingival plaque from patients with refractory periodontitis in Norway was estimated to be 68% [71]. Moreover, Larsen and co-workers [72] recently reported disparity in the resistance rates of metronidazole in Norway using two different methods for its susceptibility determination. According to their report, the number of metronidazole-resistant isolates for *Helicobacter pylori* from previously untreated Norwegian patients reduced from 23 to 8 cases as they switched test methodology from the standard European to the one outlined in the Norwegian guideline. In relation to this, a case report published as rapid communication in 2010 highlighted two cases of verified clinical failures using the internationally recommended 1st-line cefixime for gonorrhoea treatment in Norway [73].

An epidemiological analysis on MRSA from 2006 through 2010 showed the number of severe infections in Norway remained 20 cases per year in which a third of the cases are attributed to each of healthcare acquired, imported and community acquired infections [74]. Newer classes of

antimicrobials like daptomycin, quinupristin-dalfopristin and linezolid have been developed for treatment of infections with resistant gram-positive bacteria such as MRSA and vancomycin resistant *enterococci* species. Accordingly, quinupristin-dalfopristin and linezolid have already been introduced in Norway for infections caused by such resistant bacteria [75, 76]. A study by Jørgen *et al* [77] depicted complete susceptibility of MRSA to daptomycin, the 1st line drug among the new class of antibiotics for MRSA infections. Different studies conducted on the strains of bacteria with confirmed resistance towards antibiotics in Norway documented various molecular, genetic and environmental mechanisms driving the drug resistance problems in the country [78-85].

Discussion

The comprehensive measures taken in the Norwegian healthcare system, especially after the year 2000, to ensure the rational use of antibiotics seem to have impacted the practice. Such measures included institutional, regulatory and educational mechanisms aimed at establishing a functional antibiotics stewardship system in the country. The reviewed studies roughly show that Norway has managed to maintain low consumption of antibiotics thereby containing drug resistance problems over the last decade.

In the strategic document [15], the importance of guidelines in ensuring the rational use of antibiotics has been emphasized. It also acknowledges lack of uniform system, at least in some cases, for the development and maintenance of such guidelines in the Norwegian healthcare system. The strategy vowed to ensure the provision of guidelines by relevant professional circles on the use of antibiotics. It has been indicated that while various healthcare facilities may prepare their specific guidelines, such guidelines should be based on the national guidelines. Hence, there

is a great need for committing resources and proper mechanisms so that all healthcare delivery institutions in the country employ working guidelines. Besides, the limitations associated with adherence to the available guidelines for antibiotic use should also be addressed. Such problems can significantly compromise the country's efforts in maintaining its current status vis-à-vis antibiotic use and drug resistance; and hence, to which authorities must give due attention.

The positive impact of Norway's antibiotic stewardship program is visible on the country's antibiotic consumption over the last decade or so. Accordingly, Norway's population-wide consumption of antibiotics can still be said to be one of the lowest in the world. Amidst of a very fine general trend, however, overconsumption of some specific class of antibiotics like macrolides seems to remain a challenge. Such overuse might be attributed to what is commonly called 'squeezing the balloon' effect as explained by Schooneveld [86]. This means that formulary restriction or pre-authorization, the common strategy in most antibiotic stewardship programs, may effectively reduce antibiotic use and associated pharmaceutical costs but usually face resistance from the prescribers owing to its tendency to restrict what many practicing physicians call 'clinical freedom' [87]. Moreover, this approach is said to off-set its own benefit through 'squeezing the balloon' effect; whereby an increase in the use of some antimicrobial agents that select for resistance will follow as driven by the restriction or pre-authorization of others [88]. It might therefore be imperative that health authorities in Norway bring such problems to the attention of clinicians. Sales data from pharmacies are commonly used to estimate specific antibiotic consumption as is the case in some of the studies considered in this review. However, such methodological approach has recently been disputed owing to the possible differences between sales figures and actual drug use as a result of variations in stock

size over time, discarding of expired drugs, and exchanges of drugs between wards in hospitals and nursing homes [89].

It's generally recommended that for any antibiotic stewardship program to be effective, it should be either integrated or inclusive of infection prevention programs in healthcare institutions. Exemplary to many others for its comprehensiveness, the Norwegian antibiotic stewardship program has extended its scope to the institutional practices of infection prevention/control in health care facilities. Nevertheless, prevention/control efforts of TB have recently remained challenging in Norway because of immigration and international travels. WHO categorized TB as a global emergency disease thereby launched DOTS as a containment and control strategy across the globe since 1993 [90]. Accordingly, this treatment modality for TB has been effectively applied in Norway with few challenges. Yet in relation to this, it has been pointed out that MRSA is also another challenge especially among non-western immigrant children in Norway.

Prevention/control endeavors for infections have also been extended to nursing homes in Norway as per the plans in the country's strategy. Accordingly, protocols have been provided for infection prevention/control and use of antibiotics in nursing homes. The concerted effort to improve the existing practices of infection prevention and control in the Norwegian nursing homes should obviously be revitalized to maintain the favorable conditions. In any strategy that targets to control and contain antibiotic resistance, continuous ecological surveillance involving various pathogenic microbes including their drug susceptibility and profiling of resistance mechanisms will be very crucial. As indicated in the introductory part of this paper, the NORM and NORM-VET programs are playing important roles with this regard in the Norwegian

healthcare settings. In line with the reports of these programs, the findings in some studies also underscored the low antibiotic consumption and resistance rates [91, 92] that are known to characterize the country's overall conditions.

It's generally understood that different mechanisms acting alone or in concert mediate the development of drug resistance in various microorganisms and pose great challenges in the application of appropriate screening strategies and treatment modalities. Tremendous efforts have been made across various sectors in Norway to extensively study and document the resistance mechanisms and resistant-strains of microorganisms over the last decade or so. It's imperative that such efforts are sustained also in the future so that Norway remains on the headlines for the global good news concerning antibiotic use and resistance.

Conclusion

This review showed that the strategy of antibiotic stewardship in Norway is comprehensive in scope and realistic. It's integrated in various sectors and levels along subordinate agencies including at regional and local levels. The measures taken to implement the strategy to ensure the rational use of antibiotics have impacted practice in the healthcare settings. The reviewed studies roughly depicted that Norway has managed to maintain low consumption of antibiotics thereby keeping the low levels of drug resistance problems across its borders over the last decade. Few reported challenges including the use and abuse of antibiotics in nursing homes as well as pitfalls associated with adherence to institutional or national guidelines warrant utmost attention by the Norwegian health authorities and practitioners at large.

References

1. Sande-Bruinsma N, Grundmann H, Verloo D et al: **Antimicrobial Drug Use and Resistance in Europe.** *Emerg Infect Dis* 2008; 14: 1722 -1730
2. Schooneveld TV: **Antimicrobial stewardship: attempting to preserve a strategic resource.** *J Community Hosp Intern Med Perspect.* 2011, 1: 7209 - DOI: 10.3402/jchimp.v1i2.7209
3. Kiiivet RA, Dahl ML, Adria N et al: **Antibiotic Use in 3 European University Hospitals.** *Scand J Infect Dis* 1998; 30: 277–280
4. Chung GW, Wu J, Yeo CL, Chan D, Hsu LY: **Antimicrobial stewardship: A review of prospective audit and feedback systems and an objective evaluation of outcomes.** *Virulence* 2013; 4:2, 151–157
5. Olsen G: **Consumption of antibiotics in Greenland, 1964-1970; I. Economic and epidemiological considerations.** *Br J Vener Dis* 1973; 49: 20-26
6. Bartoloni A, Cuttis F, Leoni *et al*: **Patterns of antimicrobial use and antimicrobial resistance among healthy children in Bolivia.** *Trop Med Int Health* 1998; 3 (2): 116-123
7. Stichele RH, Elseviers MM, Ferech M et al: **European Surveillance of Antimicrobial Consumption (ESAC): Data Collection Performance and Methodological Approach.** *Br J Clin Pharmacol* 2004; 58 (4): 419–428

8. Ebrahimzadeh MA, Shokrzadeh M, Ramezani A: **Utilization Patterns of Antibiotics in Different Wards of Specialized Sari Imam University Hospital in Iran.** *Pak J Biol Sci* 2008; 11 (2): 275-279
9. Gemechu LA, Gutema GB, Lemango ET, Ayele AM: **Multiple drug resistance patterns of fecal isolates of enteric bacterial species in Tigray, Northern Ethiopia: A 10-year retrospective analysis.** *Journal of Pharmacy Research* 2011; 4(10): 3259-3263
10. Skudal HK, Grude N, Kristiansen B-E: **Increasing antibiotic resistance in urinary tract infections.** *Tidsskr Nor Lægeforen* 2006; 126:1058–1060
11. Dukes M.N G: **Antibiotic use and public policy.** *Int J Risk Saf Med* 17 (2005) 127–131
12. Ulf RD, Fernanda CP: **Incentives for developing new antibiotics or antimicrobial strategies.** *BMJ* 2013;346:f2136doi:10.1136/bmj.f2136(Published 8 April 2013)
13. NORM-VET 1999: **Usage of antimicrobial agents in animals and occurrence of antimicrobial resistance in bacteria from animals, feed, and food in Norway.** NORM-VET Report 1999; pp 1-28
14. NORM/NORM-VET: **Consumption of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway** (Annual reports 2000 through 2011) Available at <http://www.vetinst.no/eng/Publications/Norm-Norm-Vet-Report> (Accessed on 25th August 2013)
15. Ministry of Health and Care Services: **National strategy for prevention of infections in the health service and antibiotic resistance (2008–2012).** Available at

<http://www.regjeringen.no/en/dep/hod/Subjects/the-department-of-public-health/national-strategy-for-prevention-of-infe.html?id=528882> (last accessed on 20th August 2013)

16. MacDougall C, Polk RE: **Antimicrobial Stewardship Programs in Health Care Systems.** *Clin Microbiol Rev* 2005; 18(4): 638–56
17. Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, *et al*: **Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.** *Clin Infect Dis* 2007; 44: 159-77
18. Signe F, Kari H, Andrew DO: **Process evaluation of a cluster randomized trial of tailored interventions to implement guidelines in primary care-why is it so hard to change practice?** *Family Practice* 2003; 20 (3): 333-339.
19. Gjelstad S, Straand J, Dalen I, *et al*. **Do general practitioners' consultation rates influence their prescribing patterns of antibiotics for acute respiratory tract infections?** *J Antimicrob Chemother* 2011; 66: 2425–2433 doi:10.1093/jac/dkr295
20. Agdestein B, Lindbæk M, Gjelstad S: **Do general practitioners follow the national guidelines for treating urinary tract infections with antibiotics?** *Tidsskr Nor Legeforen* 2011; 131:1641–1644
21. Sivertsen TB, Astrøm AN, Greve G, Aßmus J, Skeie MS: **Endocarditis prophylaxis and congenital heart defects in the Norwegian Public Dental Service.** *Acta Pædiatrica* 2013; 102:29–34

22. Høye S, Frich JC, Lindbaek M: **Use and feasibility of delayed prescribing for respiratory tract infections: A questionnaire survey.** *BMC Family Practice* 2011, 12:34
23. Nordlie AL, Andersen BM: **Parents' attitude to physician's role in the prescription of antibiotics to their children.** *Tidsskr Nor Laegeforen.* 2004; 124 (17):2240-1
24. Eide TB, Hippe VC, Brekke M. **The feasibility of antibiotic dosing four times per day: A prospective observational study in primary health care.** *Scand J Prim Health Care* 2012; 30: 16–20
25. Fossum GH, Lindbæk M, Gjelstad S, et al: **Are children carrying the burden of broad-spectrum antibiotics in general practice? Prescription pattern for paediatric outpatients with respiratory tract infections in Norway.** *BMJ* 2013;3: e002285. doi:10.1136/ bmjopen-2012-002285
26. Gjelstad S, Dalen I, Lindbæk M: **GPs' antibiotic prescription patterns for respiratory tract infections—still room for improvement.** *Scand J Prim Health Care* 2009; 27:208–215
27. Fagan MS: **Can the use of antibiotics in the treatment of acute bronchitis be reduced?** *Tidsskr Nor Lægeforen* 2001; 121:455–458
28. Gjelstad S, Høye S, Straand J, Brekke M, Dalen I, Lindbæk M: **Improving antibiotic prescribing in acute respiratory tract infections: cluster randomised trial from Norwegian general practice (prescription peer academic detailing (Rx-PAD) study).** *BMJ* 2013;347:f4403doi:10.1136/bmj.f4403(Published 26 July 2013)

29. Høye S, Gjelstad S, Lindbæk M: **Effects on antibiotic dispensing rates of interventions to promote delayed prescribing for respiratory tract infections in primary care.** *Br J Gen Pract.* 2013; 63(616):e777-86. doi: 10.3399/bjgp13X674468.
30. Al-Haroni M, Skaug N: **Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption.** *J Antimicrob Chemother* 2007; 59: 1161–1166
31. Hauge SH, Blix HS, Borgen K: **Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007–08.** *Viol. J.* 2009, 6:54
doi:10.1186/1743-422X-6-54
32. Odenholt I, Bylander-Groth A, Frimodt-Moè Ller N, Rokstad KS, Lstad SM: **Differences in Antibiotic Prescribing Patterns Between General Practitioners in Scandinavia: A Questionnaire Study.** *Scand J Infect Dis* 2002; 34: 602–609
33. Eliassen KE, Fetveit A, Hjortdahl P, Berild D, Lindbaek M: **New guidelines for antibiotic use in primary health care.** *Tidsskr Nor Laegeforen.* 2008; 128 (20):2330-4.
34. Butler CC, Hood K, Verheij T et al: **Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries.** *BMJ* 2009; 338:b2242
35. Haug JB, Raastad R, Berild D: **“Look to Norway”--but for how long?** *Tidsskr Nor Laegeforen.* 2010; 130(15):1484-6

36. Lindbæk M, Jensen S, Eliassen KE, Fetveit A, Grude N, Berild D, Hjortdahl P: **New guidelines for use of antibiotics in the primary health care service.** *Tidsskr Nor Lægeforen* 2013; 133: 1052 – 3
37. Nordlie A-L, Andersen BM: **Changes in antibiotic consumption among day-care children in Oslo.** *Tidsskr Nor Lægeforen* 2007; 127: 2924–6
38. Lagerløv P, Holager T, Westergren T, Aamodt G: **The use of paracetamol and antibiotics among preschool children.** *Tidsskr Nor Lægeforen.* 2004; 124 (12):1620-3.
39. Soma M, Slapgård H, Lerberg M, Lindbæk M: **Patients' expectations of antibiotics for acute respiratory tract infections (ARTI): a questionnaire survey at the Oslo emergency centre, winter 2002 - 2003.** *Tidsskr Nor Lægeforen* 2005; 125:1994–1997
40. Blix HS, Engeland A, Litleskare I, Rønning M: **Age- and gender-specific antibacterial prescribing in Norway.** *J Antimicrob Chemother* 2007; 59: 971–976
41. Litleskare I, Blix HS, Rønning M: **Antibiotic use in Norway.** *Tidsskr Nor Lægeforen.*2008; 128(20):2324-9.
42. Krogh K, Surén P, Mengshoel AT, Brandtzæg P: **Tuberculosis among children in Oslo, Norway, from 1998 to 2009.** *Scand. J. Infect. Dis* 2010; 42: 866–872
43. Farah MG, Tverdal A, Steen TW et al: **Treatment outcome of new culture positive pulmonary tuberculosis in Norway.** *BMC Public Health* 2005, 5:14 doi:10.1186/1471-2458-5-14

44. Sagbakken M, Bjune GA, Frich JC: **Humiliation or care? A qualitative study of patients' and health professionals' experiences with tuberculosis treatment in Norway.** *Scand J Caring Sci*; 2012; 26; 313–323
45. Elstrøm P, Iversen B, Aavitsland P: **Should children adopted from abroad be screened for methicillin-resistant Staphylococcus aureus?** *Tidsskr Nor Legeforen* 2008; 128:291-3.
46. Kacelnik O, Alberg T, Mjaland O et al: **Guidelines for Antibiotic Prophylaxis of Cholecystectomies in Norwegian Hospitals.** *Surg Infect* 2013; 14:2, 188-91
47. Eriksen HM, Økland I, Langen E, et al: **Antibiotics prophylaxis in connection with caesarean section—guidelines at Norwegian maternity departments.** *Tidsskr Nor Legeforen* 2011; 131: 2355 – 8
48. Eriksen HM, Sæther AR, Løwer HL et al. **Infections after caesarean sections.** *Tidsskr Nor Legeforen* 2009; 129: 618–22
49. Schiøtz HA, Guttu K: **Value of urinary prophylaxis with methenamine in gynecologic surgery.** *Acta Obstet Gynecol Scand* 2002; 81: 743–746
50. Blom HC, Duesund R, Rotegård K, Sandness Y: **Post-operative infections at a local hospital in Norway-systematic recording for seven years.** *Tidsskr Nor Lægeforen* 2007; 127: 1640–3
51. Johansen TE, Cek M, Naber KG, Stratchounski L, Svendsen MV, Tenke P: **Hospital acquired urinary tract infections in urology departments: pathogens, susceptibility**

- and use of antibiotics, data from the PEP and PEAP-studies.** *Int J Antimicrob Agents* 2006; 28: 91-107
52. Rettedal S, Lohr IH, Nata O et al: **First outbreak of extended-spectrum beta lactamase producing *Klebsiella pneumoniae* in a Norwegian neonatal intensive care unit; associated with contaminated breast milk and resolved by strict cohorting.** *APMIS* 2012, 120: 612–621
53. Lohr IH, Rettedal S, Nata O et al: **Long-term faecal carriage in infants and intra-household transmission of CTX-M-15-producing *Klebsiella pneumoniae* following a nosocomial outbreak.** *J Antimicrob Chemother* 2013; 68: 1043–1048
54. Rettedal S, Lohr IH, Nata O et al: **Risk factors for acquisition of CTX-M-15 extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* during an outbreak in a neonatal intensive care unit in Norway.** *Scand J Infect Dis*, 2013; 45: 54–58
55. Blystad H, Ånestad G, Vestrheim DF, Madsen S, Rønning K. **Increased incidence of *Mycoplasma pneumoniae* infection in Norway 2011.** *Euro Surveill* 2012; 17(5):20074
56. Andersen BM, Rasch M, Syversen G: **Is an increase of MRSA in Oslo, Norway, associated with changed infection control policy?** *J Infect* 2007; 55(6):531-8.
57. Jakopanec I, Hassfjord JJ, Nilsen O, Larsen AL, Aavitsland P: **Local outbreak of quinolone-resistant gonorrhoea in Norway, January 2008.** *Euro Surveill* 2008, 13:4–6

58. Hommelstad J, Madsø A, Eide PK: **Significant reduction of shunt infection rate in children below 1 year of age after implementation of a perioperative protocol.** *Acta Neurochir* 2013; 155:523–531
59. Fagan M, Meahlen M, Lindbeak M, Berild D: **Antibiotic prescribing in nursing homes in an area with low prevalence of antibiotic resistance: Compliance with national guidelines.** *Scand J Prim Health Care* 2012; 30: 10–15
60. Fagan M, Skotheim SB: **Use of fluoroquinolones in nursing homes.** *Tidsskr Nor Laegeforen.* 2010;130 (20):2022-4
61. Blix HS, Bergman J, Schjøtt J: **How are antibacterials used in nursing homes? Results from a point prevalence prescription study in 44 Norwegian nursing homes** *Pharmacoepidemiol Drug Saf.* 2010; 19: 1025–1030
62. Blix HS, Røed J, Sti MO: **Large variation in antibacterial use among Norwegian nursing homes.** *Scand. J. Infect. Dis,* 2007; 39: 536-541
63. Erikse HM, Sæther AR, Viktil KK, et al: **Use of antibiotics in nursing homes-surveillance with different methods.** *Tidsskr Nor Legeforen* 2013; 133: 2052 – 6
64. Andersen B M, Rasch M: **Infections in nursing homes in Oslo.** *Tidsskr Nor Lægeforen* 2002; 122:2371–2373
65. Bergman J, Schjøtt J, Blix HS: **Prevention of urinary tract infections in nursing homes: lack of evidence-based prescription?** *BMC Geriatrics* 2011 11:69. doi:10.1186/1471-2318-11-69

66. Eriksen HM, Iversen BG, Aavitsland P: **Prevalence of nosocomial infections and use of antibiotics in long-term care facilities in Norway, 2002 and 2003.** *J Hosp Infect* 2004; 57, 316–320
67. Eriksen HM, Elstrøm P, Harthug S, Akselsen PE: **Infection control in long-term care facilities for the elderly.** *Tidsskr Nor Lægeforen* 2005; 125:1835–1837
68. Litherland AT: **Urinary tract infection: diabetic women’s strategies for prevention.** *BJN* 2011; 20(13): 791-6
69. Lindemann PC, Risberg K, Wiker HG, Mylvaganam H: **Aminoglycoside resistance in clinical Escherichia coli and Klebsiella pneumoniae isolates from Western Norway.** *APMIS* 2011; 120: 495–502
70. Claesson C, Hallgren A, Nilsson M et al: **Susceptibility of staphylococci and enterococci to antimicrobial agents at different ward levels in four north European countries.** *Scand J Infect Dis* 2007; 39: 1002-1012
71. Handal T, Caugant DA, Olsen I: **Antibiotic Resistance in Bacteria Isolated from Subgingival Plaque in a Norwegian Population with Refractory Marginal Periodontitis.** *Antimicrob. Agents Chemother.* 2003; 47(4): 1443–1446
72. Larsen AL, Ragnhildstveit E, Moayeri B, Eliassen L, Melby KK: **Resistance rates of metronidazole and other antibacterials in Helicobacter pylori from previously untreated patients in Norway.** *APMIS* 2012; 121: 353–358, DOI 10.1111/apm.12009

73. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H: **Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010.** *Euro Surveill.* 2010; 15(47): 19721.
74. Elstrøm P, Kacelnik O, Bruun T et al: **Meticillin-resistant *Staphylococcus aureus* in Norway, a low-incidence country, 2006-2010.** *J Hosp Infect* 2012; 80: 36-40
75. Simonsen GS, Bergh K, Bevanger L, Digranes A, Gaustad P, Melby KK, Høiby EA: **Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of Gram-positive cocci from Norway.** *Scand J Infect Dis.* 2004; 36 (4):254-8
76. Brubakk O, Bjørneklett A, Sjørnsen H, Vigen B: **Use of a new antibiotic in Norway.** *Tidsskr Nor Lægeforen* 2007; 127:1931–1932
77. Jørgen B, Merckoll P, Melby KK: **Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive *S.aureus* from the Oslo area.** *Scand J Infect Dis* 2007; 39: 1059-1062
78. Domingues S, Nielsen KM, Silva GJ: **Various pathways leading to the acquisition of antibiotic resistance by natural transformation.** *Mob Genet Elements*, 2012; 2:6, 257-260
79. Unemo M, Golparian D, Skogen V: ***Neisseria gonorrhoeae* Strain with High-Level Resistance to Spectinomycin Due to a Novel Resistance Mechanism (Mutated Ribosomal Protein S5) Verified in Norway.** *Antimicrob. Agents Chemother* 2013; 57(2): 1057–1061

80. Tofteland S, Dahl KH, Aasnæs B, Sundsfjord A, Naseer U: **A nationwide study of mechanisms conferring reduced susceptibility to extended-spectrum cephalosporins in clinical *Escherichia coli* and *Klebsiella* spp. Isolates.** *Scand J Infect Dis* 2012; 44: 927–933
81. Aamot HA, Blomfeldt A, Eskesen AN: **Genotyping of 353 *Staphylococcus aureus* Bloodstream Isolates Collected between 2004 and 2009 at a Norwegian University Hospital and Potential Associations with Clinical Parameters.** *J Clin Microbiol* 2012; 50(9):3111–3114
82. Aamot HV, Blomfeldt A, Skråmm I, Müller F, Monecke S: **Molecular characterisation of methicillin-sensitive *Staphylococcus aureus* from deep surgical site infections in orthopaedic patients.** *Eur J Clin Microbiol Infect Dis* 2012; 31:1999–2004
83. Hjelmevoll SO, Golparian D, Dedi L et al: **Phenotypic and genotypic properties of *Neisseria gonorrhoeae* isolates in Norway in 2009: antimicrobial resistance warrants an immediate change in national management guidelines.** *Eur J Clin Microbiol Infect Dis* 2012; 31:1181–1186
84. Sun J, Sundsfjord A, Song X: ***Enterococcus faecalis* from patients with chronic periodontitis: virulence and antimicrobial resistance traits and determinants.** *Eur J Clin Microbiol Infect Dis* 2012; 31:267–272
85. Sogstad MKR, Littauer P, Aaberge IS, Caugant DA, Høiby EA: **Rapid Spread in Norway of an Erythromycin-Resistant Pneumococcal Clone, Despite Low Usage of Macrolides.** *Microb Drug Resist.* 2007; 13(1): 29-36

86. Radyowijati A, Haak H: **Determinants of Antibiotic Use in the Developing World.** Child Health Research Project Special Report 2002; 1-39
87. Phillips I: **Prudent use of antibiotics: are our expectations justified?** *Clin Infect Dis* 2001; 33(Suppl. 3):S130–132
88. Burke JP: **Antibiotic Resistance-Squeezing the Balloon?** *JAMA* 1998; 280: 1270-1
89. Haug JB, Myhr R, Reikvam Å: **Pharmacy sales data versus ward stock accounting for the surveillance of broad-spectrum antibiotic use in hospitals.** *BMC Medical Research Methodology* 2011; 11:166.
90. Grange JM, Zumla A: **The global emergency of tuberculosis: what is the cause?** *J R Soc Promot Health* 2002; 122(2):78-81
91. Haug JB, Berild D, Walberg M, Reikvam AS: **Increased antibiotic use in Norwegian hospitals despite a low antibiotic resistance rate.** *J Antimicrob. Chemother* 2011; 66: 2643–2646
92. Aldrin M, Raastad R, Tvette IF *et al*: **Antibiotic resistance in hospitals: a ward-specific random effect model in a low antibiotic consumption environment.** *Stat. Med.* 2013, 32:1407–1418